Main Article Content
OBJECTIVE: To evaluate the efficacy and safety of methotrexate in chronic actinic dermatitis.
METHODS: Clinically and biopsy proven cases of chronic actinic dermatitis were included in study after fulfilling the inclusion criteria. Patients were given methotrexate according to protocol and efficacy was noted according to improvement in Psoriasis Area and Severity Index (PASI) score. Side effects were noted for safety evaluation.
RESULTS: A total of thirty patients, 27 male and 3 females, with a mean age of 57.5±9.91 years, were included in study. Duration of disease was <1year in 5 patients, 2-5years in 14 patients, 6-10year in 8 patients and >10 years in 6 patients.
Twenty seven patients received 10mg and 3 patients received dose of 15mg.Twenty nine patients completed 6 months of methotrexate therapy. One patient stopped treatment because of mild gastrointestinal side effects and deranged Liver Function Tests (LFTs). SGPT was 3 time above normal when treatment was stopped. Patients were evaluated at 1st week, 4th week and monthly for 6 months. Six patients (20%) showed complete recovery, 13(43%) showed 50-75% recovery, 7 (23%) showed 25-49% recovery while rest showed no improvement. Means of initial and final PASI score showed significant results with P<0.0001. The clinical response to treatment was observed at 4-6 weeks which reached to maximum in 4-6 months.
We found methotrexate to be a potentially efficacious and safe drug in the treatment and asteroid sparing drug in chronic actinic dermatitis.
KEY WORDS: Photosensitivity Disorders (MeSH); Chronic Actinic Dermatitis (MeSH); Efficacy (Non-MeSH); Methotrexate (MeSH); Safety (MeSH).
Work published in KMUJ is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
1. Hsiao TL, Chu CY. Chronic actinic dermatitis – A clinical study of 15 cases in Northern Taiwan. Dermatologica Sinica 2014;32(2): 82-6.
2. Somani VK. Chronic actinic dermatitis -- A study of clinical features. Indian J Dermatol Venereol Leprol 2005;71(6):409-13.
3. Paek SY, lim HW. Chronic actinic dermatitis. Dermatol Clin 2014;32(3):355-61. DOI: 10.1016/j.det.2014.03.007.
4. Sidiropoulos M, Deonizio J, Martinez-Escala ME, Gerami P, Guitart J. Chronic actinic dermatitis/actinic reticuloid: a clinicopathologic and immunohistochemical analysis of 37 cases. Am J Dermatopathol 2014;36(11):875-81. DOI: 10.1097/DAD.0000000000000076.
5. Naqqash S, Asad F, Pal SS. Efficacy and safety of azathioprine in chronic actinic dermatitis” J Pak Assoc Dermatol 2010;20(4):222-6.
6. Walia NS, Kumar N, Jaiswal AK. Azathioprine as corticosteroid sparing drug in chronic actinic dermatitis. Med J Armed Forces India. 2000;56(1):77-8.
7. Dawe RS, Ferguson J. Diagnosis and treatment of chronic actinic dermatitis. In dermatol Ther 2003;16(1):45-51.
8. Morris RE. New small molecule immunosuppressants for transplantation: Review of essential concepts. J Heart Lung Transplant 1993;12(6 Pt 2):S275-86.
9. Bareham CR, Griswold DE, Calabresi P. Synergism of Methotrexate with Imuran and with 5-Fluorouracil and Their Effects on Hemolysin Plaque-forming Cell Production in the Mouse. Cancer Res 1974;34(3):571-5.
10 Salliot C, van der Heidje D. Long-term safety of metrhotrexate monotheraoy in patients with rheumatoid arthiritis: a systematic literature search. Ann Rheum Dis 2009;68(7):1100-4. DOI: 10.1136/ard.2008.093690.
11. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991 Aug 25(2 Pt 1):306-18. DOI: 10.1016/0190-9622(91)70199-C
12. Sotoudehmanesh R, Anvari B, Akhlaghi M, Shahraeeni S, Kolahdoozan S. Methotrexate Hepatotoxicity in Patients with Rheumatoid Arthritis. Middle East J Dig Dis 2010 Sep;2(2):104-9.
13. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26: 55-62.
14. Agarwal V, Chauhan S, Singh R, Sachdev A, D’Cruz S, Tahlan A. Pancytopenia with the first dose of methotrexate in a patient with psoriatic arthritis. J Indian Rheumatol Assoc 2005;13:60-1.
15. Güler N, Tander B, Kisacik B, Utku U, Çevik A, Erçolak V et al. Low Dose Methotrexate Associated Pancytopenia in a Patient with Rheumatoid Arthritis. Turk J Phys Med Rehab 2008 Jun 1;54(2):79-81.
16. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985 Dec;12 Suppl 12: 35-9.
17. Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996 Feb;39(2):272-6. DOI: 10.1002/art.1780390214